Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Neuroendocrine carcinoma of the skin
ADR ID BADD_A03040
ADR Hierarchy
05      Endocrine disorders
05.08      Neoplastic and ectopic endocrinopathies
05.08.01      Endocrine neoplasms NEC
05.08.01.009      Neuroendocrine carcinoma of the skin
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.03      Skin neoplasms malignant and unspecified
16.03.02      Skin neoplasms malignant and unspecified (excl melanoma)
16.03.02.008      Neuroendocrine carcinoma of the skin
23      Skin and subcutaneous tissue disorders
23.08      Skin neoplasms malignant and unspecified
23.08.02      Skin neoplasms malignant and unspecified (excl melanoma)
23.08.02.008      Neuroendocrine carcinoma of the skin
Description A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245) [MeSH]
MedDRA Code 10029266
MeSH ID D015266
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Neuroendocrine carcinoma of the skin | Merkel cell carcinoma | Carcinoma, Merkel Cell | Merkle Tumors | Tumors, Merkle | Merkel Cell Tumor | Tumor, Merkel Cell | Merkel Cell Cancer | Cancer, Merkel Cell | Cell Cancer, Merkel | Merkel Cell Carcinoma
ADR Related Proteins
Protein Name UniProt AC TTD Target ID
Not AvailableNot AvailableNot Available
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00041Adalimumab--
BADD_D01110Hydroxyurea0.000139%
BADD_D01119Ibrutinib0.000347%
BADD_D01253Lenalidomide0.000604%
BADD_D01507Mycophenolate mofetil0.000341%
BADD_D01834Prednisone0.000040%
BADD_D01978Ruxolitinib0.000208%
BADD_D02105Tacrolimus0.000555%
BADD_D02236Tofacitinib0.000302%
BADD_D02344Vemurafenib0.000113%
BADD_D02369Voriconazole0.038197%
BADD_D02464Fingolimod0.001208%
The 1th Page    1    Total 1 Pages